First AD

Second AD

Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses @ ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC 

Please discuss recent analyses from the CLEAR study, evaluating lenvatinib + pembro in frontline advanced RCC. 

Efficacy by baseline tumor size (Grunwald, et al. ASCO GU 2024. Abstract 364)

Biomarker analysis (Motzer et al. ASCO 2024 Abstract 4504)

Network meta-analysis– len + pembro vs other 1L treatments in advanced RCC (Grunwald, et al. ASCO GU 2024. Abstract 482)

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma

Peer Exchange

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC). 

Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC